Núria Laínez

1.9k total citations
77 papers, 1.1k citations indexed

About

Núria Laínez is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Núria Laínez has authored 77 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 29 papers in Surgery and 29 papers in Oncology. Recurrent topics in Núria Laínez's work include Bladder and Urothelial Cancer Treatments (19 papers), Renal cell carcinoma treatment (13 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Núria Laínez is often cited by papers focused on Bladder and Urothelial Cancer Treatments (19 papers), Renal cell carcinoma treatment (13 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Núria Laínez collaborates with scholars based in Spain, United States and Italy. Núria Laínez's co-authors include Antonio Casado, Andrés Poveda, Javier Martín‐Broto, Joan Maurel, Ana De Juan, J. Buesa, Xavier García del Muro, José Ángel Arranz, Javier Puente and Pablo Maroto and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Núria Laínez

64 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Núria Laínez Spain	16	672	432	353	327	141	77	1.1k
Ricardo Cubedo Spain	14	637 0.9×	223 0.5×	196 0.6×	566 1.7×	131 0.9×	50	1.1k
Katsunari Takifuji Japan	21	528 0.8×	716 1.7×	241 0.7×	551 1.7×	79 0.6×	98	1.3k
Eunmi Nam South Korea	15	660 1.0×	295 0.7×	192 0.5×	513 1.6×	129 0.9×	30	1.1k
Bala Başak Öven Ustaalıoğlu Türkiye	16	433 0.6×	365 0.8×	110 0.3×	523 1.6×	107 0.8×	83	1.1k
Eduardo Fernandes United States	22	538 0.8×	767 1.8×	79 0.2×	456 1.4×	261 1.9×	71	1.5k
Akiyoshi Kasuga Japan	18	725 1.1×	535 1.2×	321 0.9×	755 2.3×	73 0.5×	96	1.4k
Daniel P. Nussbaum United States	25	945 1.4×	946 2.2×	76 0.2×	1.2k 3.6×	78 0.6×	83	1.8k
Yukiyoshi Esaki Japan	20	358 0.5×	607 1.4×	126 0.4×	569 1.7×	194 1.4×	52	1.3k
Olivier Collard France	16	1.1k 1.6×	182 0.4×	116 0.3×	681 2.1×	145 1.0×	67	1.6k
Christine Rebischung France	16	416 0.6×	362 0.8×	90 0.3×	570 1.7×	125 0.9×	34	935

Countries citing papers authored by Núria Laínez

Since Specialization

Citations

This map shows the geographic impact of Núria Laínez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Núria Laínez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Núria Laínez more than expected).

Fields of papers citing papers by Núria Laínez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Núria Laínez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Núria Laínez. The network helps show where Núria Laínez may publish in the future.

Co-authorship network of co-authors of Núria Laínez

This figure shows the co-authorship network connecting the top 25 collaborators of Núria Laínez. A scholar is included among the top collaborators of Núria Laínez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Núria Laínez. Núria Laínez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Rodríguez-Moreno, Juan Francisco, Guillermo de Velasco, Carlos Álvarez-Fernández, et al.. (2025). Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial. Clinical Cancer Research. 31(9). 1644–1656.

2.

Peláez, Mireia, et al.. (2025). Avelumab maintenance in advanced urothelial carcinoma: real-world data from Northern Spain (AVEBLADDER study). Clinical & Translational Oncology. 27(12). 4481–4492.

3.

Linares, Estefanía, I. Rivero Belenchón, Gemma Sancho, et al.. (2024). PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform.. Journal of Clinical Oncology. 42(23_suppl). 192–192.

4.

García-Donás, Jesús, Andrés Redondo, Ana Santaballa, et al.. (2024). Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016–01). Gynecologic Oncology. 191. 233–239.

5.

Gebski, Val, Florence Joly, Jonathan A. Ledermann, et al.. (2024). Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer. Gynecologic Oncology. 192. 50–55.

6.

Linares, Estefanía, I. Rivero Belenchón, Gemma Sancho, et al.. (2024). PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform.. Journal of Clinical Oncology. 42(16_suppl). e23190–e23190. 1 indexed citations

7.

Climent, Miguel Ángel, Carlos Álvarez-Fernández, Rafael Morales, et al.. (2023). Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial. Clinical & Translational Oncology. 26(6). 1532–1538. 3 indexed citations

8.

Santos, María, Javier Lanillos, Juan María Roldán‐Romero, et al.. (2021). Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma. Genetics in Medicine. 23(4). 698–704. 13 indexed citations

9.

Colombo, Nicoletta, Justine Gantzer, Beyhan Ataseven, et al.. (2020). 812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Annals of Oncology. 31. S614–S614. 2 indexed citations

10.

Lázaro-Quintela, Martín, Begoña P. Valderrama, Cristina Suárez, et al.. (2020). SEOM clinical guideline for treatment of kidney cancer (2019). Clinical & Translational Oncology. 22(2). 256–269. 17 indexed citations

11.

Alba, Aranzazu González del, Guillermo de Velasco, Núria Laínez, et al.. (2018). SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018). Clinical & Translational Oncology. 21(1). 64–74. 15 indexed citations

12.

Santaballa, Ana, Yolanda García García, Ana Herrero, et al.. (2017). SEOM clinical guidelines in gestational trophoblastic disease (2017). Clinical & Translational Oncology. 20(1). 38–46. 28 indexed citations

13.

Font, Albert, Begoña Pérez‐Valderrama, Juan Antonio Virizuela, et al.. (2016). Randomized, placebo-controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC)—SOGUG 2011-02.. Journal of Clinical Oncology. 34(15_suppl). 4529–4529. 3 indexed citations

14.

Maurel, Joan, Antonio López–Pousa, Silvia Calabuig‐Fariñas, et al.. (2016). Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. PubMed. 6(1). 10–10. 1 indexed citations

15.

Puente, Javier, Xavier García del Muro, Álvaro Pinto, et al.. (2015). Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations. Targeted Oncology. 11(2). 129–141. 1 indexed citations

16.

Bellmunt, Joaquim, et al.. (2014). SEOM clinical guidelines for the treatment of renal cell carcinoma. Clinical & Translational Oncology. 16(12). 1043–1050. 32 indexed citations

17.

Muro, Xavier García del, Antonio López–Pousa, Joan Maurel, et al.. (2011). Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study. Journal of Clinical Oncology. 29(18). 2528–2533. 197 indexed citations

18.

Martín‐Broto, Javier, Xavier García del Muro, A Gutiérrez, et al.. (2011). KIT, DOG1, PDGFR, and IGFR1 gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.. Journal of Clinical Oncology. 29(15_suppl). 10047–10047.

19.

Guarch, Rosa, et al.. (2004). Metástasis ovárica de melanona maligno de tumor primario de origen desconocido. 27(3).

20.

Arrarás, Juan Ignacio, et al.. (2004). La evaluación de la calidad de vida del paciente oncológico. El grupo de calidad de vida de la EORTC. SHILAP Revista de lepidopterología. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact